The therapeutic efficacy of the combination treatment of anti-PD-1 and BGB324 was found to be STING-dependent, as evident by the loss of anti-tumor effect and the reduced immunostimulatory effect upon STING inhibition by its inhibitor H-151 in the combination treatment group (Suppl. The gene discussed is STING1; the disease is neoplasm.